CZ282783B6 - Farmaceutické sloučeniny - Google Patents
Farmaceutické sloučeniny Download PDFInfo
- Publication number
- CZ282783B6 CZ282783B6 CZ931024A CZ102493A CZ282783B6 CZ 282783 B6 CZ282783 B6 CZ 282783B6 CZ 931024 A CZ931024 A CZ 931024A CZ 102493 A CZ102493 A CZ 102493A CZ 282783 B6 CZ282783 B6 CZ 282783B6
- Authority
- CZ
- Czechia
- Prior art keywords
- carbon atoms
- alkyl
- derivatives
- formula
- methyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 63
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 8
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 7
- 208000015114 central nervous system disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims 2
- 238000005804 alkylation reaction Methods 0.000 claims 2
- -1 prop-2-enyl Chemical group 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DGKCGLWUGYQUHU-UHFFFAOYSA-N 10-(cyclopropylmethyl)-2-methyl-4-(4-methylpiperazin-1-yl)thieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C(C=1C=C(C)SC=11)=NC2=CC=CC=C2N1CC1CC1 DGKCGLWUGYQUHU-UHFFFAOYSA-N 0.000 description 1
- KGHSDCREGXYYAW-UHFFFAOYSA-N 10-(cyclopropylmethyl)-7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)thieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C(C=1C=C(C)SC=11)=NC2=CC(F)=CC=C2N1CC1CC1 KGHSDCREGXYYAW-UHFFFAOYSA-N 0.000 description 1
- WAFRMCDMYLJLIZ-UHFFFAOYSA-N 10-benzyl-2-methyl-4-(4-methylpiperazin-1-yl)thieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C(C=1C=C(C)SC=11)=NC2=CC=CC=C2N1CC1=CC=CC=C1 WAFRMCDMYLJLIZ-UHFFFAOYSA-N 0.000 description 1
- YHVAJURGUXIEDF-UHFFFAOYSA-N 10-butyl-2-methyl-4-(4-methylpiperazin-1-yl)thieno[2,3-b][1,5]benzodiazepine Chemical compound N=1C2=CC=CC=C2N(CCCC)C=2SC(C)=CC=2C=1N1CCN(C)CC1 YHVAJURGUXIEDF-UHFFFAOYSA-N 0.000 description 1
- KGGVZZRBICZAFP-UHFFFAOYSA-N 10-ethyl-2-methyl-4-(4-methylpiperazin-1-yl)thieno[2,3-b][1,5]benzodiazepine Chemical compound N=1C2=CC=CC=C2N(CC)C=2SC(C)=CC=2C=1N1CCN(C)CC1 KGGVZZRBICZAFP-UHFFFAOYSA-N 0.000 description 1
- NSZYRHNOORJFKI-UHFFFAOYSA-N 10-ethyl-7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)thieno[2,3-b][1,5]benzodiazepine Chemical compound N=1C2=CC(F)=CC=C2N(CC)C=2SC(C)=CC=2C=1N1CCN(C)CC1 NSZYRHNOORJFKI-UHFFFAOYSA-N 0.000 description 1
- IKJAUWADCAXADK-UHFFFAOYSA-N 2,10-dimethyl-4-(4-methylpiperazin-1-yl)thieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2N(C)C2=C1C=C(C)S2 IKJAUWADCAXADK-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical class 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- XIPTXVFRLKKQTO-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10-(2-methylpropyl)thieno[2,3-b][1,5]benzodiazepine Chemical compound N=1C2=CC=CC=C2N(CC(C)C)C=2SC(C)=CC=2C=1N1CCN(C)CC1 XIPTXVFRLKKQTO-UHFFFAOYSA-N 0.000 description 1
- GGDRQRXBRXPYBZ-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10-pentylthieno[2,3-b][1,5]benzodiazepine Chemical compound N=1C2=CC=CC=C2N(CCCCC)C=2SC(C)=CC=2C=1N1CCN(C)CC1 GGDRQRXBRXPYBZ-UHFFFAOYSA-N 0.000 description 1
- IAFPIXLYZNTPSP-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10-prop-2-enylthieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2N(CC=C)C2=C1C=C(C)S2 IAFPIXLYZNTPSP-UHFFFAOYSA-N 0.000 description 1
- KTEXQPWZUCHZPR-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10-prop-2-ynylthieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2N(CC#C)C2=C1C=C(C)S2 KTEXQPWZUCHZPR-UHFFFAOYSA-N 0.000 description 1
- REZMGIQQFQHHOL-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10-propan-2-ylthieno[2,3-b][1,5]benzodiazepine Chemical compound N=1C2=CC=CC=C2N(C(C)C)C=2SC(C)=CC=2C=1N1CCN(C)CC1 REZMGIQQFQHHOL-UHFFFAOYSA-N 0.000 description 1
- NAOTVQQOIPSTBP-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10-propylthieno[2,3-b][1,5]benzodiazepine Chemical compound N=1C2=CC=CC=C2N(CCC)C=2SC(C)=CC=2C=1N1CCN(C)CC1 NAOTVQQOIPSTBP-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 102000035038 5-HT1 receptors Human genes 0.000 description 1
- 108091005478 5-HT1 receptors Proteins 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OVQUJIUVXJHHJE-UHFFFAOYSA-N 7-fluoro-2,10-dimethyl-4-(4-methylpiperazin-1-yl)thieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC(F)=CC=C2N(C)C2=C1C=C(C)S2 OVQUJIUVXJHHJE-UHFFFAOYSA-N 0.000 description 1
- SAIOMRFTOMRIEH-UHFFFAOYSA-N 7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)-10-prop-2-enylthieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC(F)=CC=C2N(CC=C)C2=C1C=C(C)S2 SAIOMRFTOMRIEH-UHFFFAOYSA-N 0.000 description 1
- GGWAWEUJULDZAY-UHFFFAOYSA-N 7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)-10-prop-2-ynylthieno[2,3-b][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=NC2=CC(F)=CC=C2N(CC#C)C2=C1C=C(C)S2 GGWAWEUJULDZAY-UHFFFAOYSA-N 0.000 description 1
- FJTYTMISBXOUDQ-UHFFFAOYSA-N 7-fluoro-2-methyl-4-(4-methylpiperazin-1-yl)-10-propylthieno[2,3-b][1,5]benzodiazepine Chemical compound N=1C2=CC(F)=CC=C2N(CCC)C=2SC(C)=CC=2C=1N1CCN(C)CC1 FJTYTMISBXOUDQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JBHUBOISLBWHAR-UHFFFAOYSA-N Flumezapine Chemical compound C1CN(C)CCN1C1=NC2=CC(F)=CC=C2NC2=C1C=C(C)S2 JBHUBOISLBWHAR-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929211379A GB9211379D0 (en) | 1992-05-29 | 1992-05-29 | Pharmaceutical compounds |
| GB939309025A GB9309025D0 (en) | 1993-04-30 | 1993-04-30 | Pharmaceutical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ102493A3 CZ102493A3 (en) | 1993-12-15 |
| CZ282783B6 true CZ282783B6 (cs) | 1997-10-15 |
Family
ID=26300951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ931024A CZ282783B6 (cs) | 1992-05-29 | 1993-05-28 | Farmaceutické sloučeniny |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0582368B1 (OSRAM) |
| JP (1) | JP3219541B2 (OSRAM) |
| CN (1) | CN1043994C (OSRAM) |
| AT (1) | ATE198891T1 (OSRAM) |
| AU (1) | AU668159B2 (OSRAM) |
| CA (1) | CA2097016A1 (OSRAM) |
| CZ (1) | CZ282783B6 (OSRAM) |
| DE (1) | DE69329887T2 (OSRAM) |
| DK (1) | DK0582368T3 (OSRAM) |
| ES (1) | ES2153373T3 (OSRAM) |
| FI (1) | FI101538B (OSRAM) |
| GR (1) | GR3035587T3 (OSRAM) |
| HU (1) | HU218278B (OSRAM) |
| IL (1) | IL105827A (OSRAM) |
| MX (1) | MX9303124A (OSRAM) |
| MY (1) | MY109943A (OSRAM) |
| NO (1) | NO305125B1 (OSRAM) |
| NZ (1) | NZ247703A (OSRAM) |
| PT (1) | PT582368E (OSRAM) |
| RU (1) | RU2125574C1 (OSRAM) |
| TW (1) | TW268005B (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| US5574028A (en) * | 1994-10-31 | 1996-11-12 | Eli Lilly And Company | Method for treating anxiety |
| EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
| EG24221A (en) * | 1995-03-24 | 2008-11-10 | Lilly Co Eli | Process for preparing olanzapine |
| CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
| US5891461A (en) * | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
| US6258807B1 (en) * | 1996-03-25 | 2001-07-10 | Eli Lilly And Company | Method for treating pain |
| CA2250186A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating migraine pain |
| AU725556B2 (en) * | 1996-03-25 | 2000-10-12 | Eli Lilly And Company | Method for treating pain |
| ZA978515B (en) * | 1996-09-23 | 1999-03-23 | Lilly Co Eli | Intermediates and process for preparing olanzapine |
| CA2266444C (en) * | 1996-09-23 | 2007-01-09 | Eli Lilly And Company | Olanzapine dihydrate d |
| CZ98899A3 (cs) * | 1996-09-24 | 1999-12-15 | Eli Lilly And Company | Složení potahovaných částic |
| RU2185383C1 (ru) * | 2001-05-22 | 2002-07-20 | Институт молекулярной генетики РАН | ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН |
| US9465041B2 (en) | 2012-08-21 | 2016-10-11 | Janssen Pharmaceutica Nv | Antibodies to paliperidone and use thereof |
| JP6450314B2 (ja) | 2012-08-21 | 2019-01-09 | ヤンセン ファーマシューティカ エヌ．ベー． | クエチアピンハプテンに対する抗体及びその使用 |
| EP2888287A4 (en) | 2012-08-21 | 2016-04-20 | Ortho Clinical Diagnostics Inc | ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE |
| ES2645433T3 (es) | 2012-08-21 | 2017-12-05 | Janssen Pharmaceutica, N.V. | Haptenos de quetiapina para su uso en inmunoensayos |
| PL2888592T3 (pl) | 2012-08-21 | 2018-03-30 | Janssen Pharmaceutica Nv | Przeciwciała względem kwetiapiny i ich zastosowania |
| EP3492473B1 (en) * | 2012-08-21 | 2025-07-30 | Janssen Pharmaceutica NV | Haptens of olanzapine |
| US9394354B2 (en) | 2012-08-21 | 2016-07-19 | Janssen Pharmaceutica Nv | Haptens of paliperidone |
| US9751953B2 (en) | 2012-08-21 | 2017-09-05 | Janssen Pharmaceutica Nv | Antibodies to risperidone haptens and use thereof |
| EP3581195B1 (en) | 2012-08-21 | 2025-10-01 | Janssen Pharmaceutica NV | Antibodies to olanzapine haptens and use thereof |
| JP6131414B2 (ja) | 2012-08-21 | 2017-05-24 | ヤンセン ファーマシューティカ エヌ．ベー． | アリピプラゾールのハプテン及びイムノアッセイにおけるそれらの使用 |
| AU2013305936B2 (en) | 2012-08-21 | 2017-08-03 | Saladax Biomedical Inc. | Haptens of risperidone and paliperidone |
| AU2013305887B2 (en) | 2012-08-21 | 2018-02-22 | Saladax Biomedical Inc. | Antibodies to risperidone and use thereof |
| PL2888373T3 (pl) | 2012-08-21 | 2018-08-31 | Janssen Pharmaceutica Nv | Przeciwciała dla arypiprazolu i ich zastosowanie |
| AU2013305901B2 (en) | 2012-08-21 | 2017-10-26 | Saladax Biomedical Inc. | Antibodies to olanzapine and use thereof |
| CN104736567B (zh) | 2012-08-21 | 2019-09-03 | 詹森药业有限公司 | 阿立哌唑半抗原的抗体及其用途 |
| MA44067A (fr) | 2015-12-17 | 2018-10-24 | Janssen Pharmaceutica Nv | Anticorps dirigés contre la quétiapine et utilisation associée |
| CA3008809A1 (en) | 2015-12-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Antibodies to risperidone and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH569731A5 (OSRAM) * | 1972-04-04 | 1975-11-28 | Wander Ag Dr A | |
| US3962248A (en) * | 1972-04-04 | 1976-06-08 | Sandoz, Inc. | Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines |
| SU629879A3 (ru) * | 1974-11-26 | 1978-10-25 | Лилли Индастриз Лимитед, (Фирма) | Способ получени тиено(1,5) бензодиазепинов или их солей |
| US4061752A (en) * | 1975-08-06 | 1977-12-06 | Sandoz Ltd. | 6-Piperazino-11-methylene-dibenzazepines[b,e] |
| FI762646A7 (OSRAM) * | 1975-09-24 | 1977-03-25 | Sandoz Ag | |
| CH624682A5 (OSRAM) * | 1976-11-10 | 1981-08-14 | Sandoz Ag | |
| US4761411A (en) * | 1983-05-18 | 1988-08-02 | Hoechst-Roussel Pharmaceuticals Inc. | Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses |
| GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
-
1993
- 1993-05-26 TW TW082104161A patent/TW268005B/zh active
- 1993-05-26 DE DE69329887T patent/DE69329887T2/de not_active Expired - Fee Related
- 1993-05-26 NO NO931917A patent/NO305125B1/no not_active IP Right Cessation
- 1993-05-26 AU AU39807/93A patent/AU668159B2/en not_active Ceased
- 1993-05-26 ES ES93304102T patent/ES2153373T3/es not_active Expired - Lifetime
- 1993-05-26 NZ NZ247703A patent/NZ247703A/en unknown
- 1993-05-26 CA CA002097016A patent/CA2097016A1/en not_active Abandoned
- 1993-05-26 AT AT93304102T patent/ATE198891T1/de not_active IP Right Cessation
- 1993-05-26 DK DK93304102T patent/DK0582368T3/da active
- 1993-05-26 PT PT93304102T patent/PT582368E/pt unknown
- 1993-05-26 EP EP93304102A patent/EP0582368B1/en not_active Expired - Lifetime
- 1993-05-27 MX MX9303124A patent/MX9303124A/es not_active IP Right Cessation
- 1993-05-28 CN CN93108212A patent/CN1043994C/zh not_active Expired - Fee Related
- 1993-05-28 MY MYPI93001036A patent/MY109943A/en unknown
- 1993-05-28 JP JP12642993A patent/JP3219541B2/ja not_active Expired - Fee Related
- 1993-05-28 HU HU9301579A patent/HU218278B/hu not_active IP Right Cessation
- 1993-05-28 RU RU93005057A patent/RU2125574C1/ru active
- 1993-05-28 CZ CZ931024A patent/CZ282783B6/cs not_active IP Right Cessation
- 1993-05-28 FI FI932445A patent/FI101538B/fi active
- 1993-05-28 IL IL10582793A patent/IL105827A/xx not_active IP Right Cessation
-
2001
- 2001-03-15 GR GR20010400431T patent/GR3035587T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MY109943A (en) | 1997-10-31 |
| DK0582368T3 (da) | 2001-02-05 |
| CZ102493A3 (en) | 1993-12-15 |
| DE69329887D1 (de) | 2001-03-01 |
| NZ247703A (en) | 1995-07-26 |
| MX9303124A (es) | 1993-11-01 |
| NO305125B1 (no) | 1999-04-06 |
| EP0582368A1 (en) | 1994-02-09 |
| AU668159B2 (en) | 1996-04-26 |
| FI932445L (fi) | 1993-11-30 |
| EP0582368B1 (en) | 2001-01-24 |
| DE69329887T2 (de) | 2001-05-23 |
| CN1085903A (zh) | 1994-04-27 |
| PT582368E (pt) | 2001-05-31 |
| FI101538B1 (fi) | 1998-07-15 |
| AU3980793A (en) | 1993-12-02 |
| ES2153373T3 (es) | 2001-03-01 |
| RU2125574C1 (ru) | 1999-01-27 |
| HU9301579D0 (en) | 1993-09-28 |
| NO931917D0 (no) | 1993-05-26 |
| NO931917L (no) | 1993-11-30 |
| FI101538B (fi) | 1998-07-15 |
| JPH0687862A (ja) | 1994-03-29 |
| JP3219541B2 (ja) | 2001-10-15 |
| GR3035587T3 (en) | 2001-06-29 |
| TW268005B (OSRAM) | 1996-01-11 |
| FI932445A0 (fi) | 1993-05-28 |
| HU218278B (en) | 2000-07-28 |
| CA2097016A1 (en) | 1993-11-30 |
| HUT66180A (en) | 1994-09-28 |
| CN1043994C (zh) | 1999-07-07 |
| IL105827A (en) | 1997-02-18 |
| IL105827A0 (en) | 1993-09-22 |
| ATE198891T1 (de) | 2001-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ282783B6 (cs) | Farmaceutické sloučeniny | |
| JP2527860B2 (ja) | チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン誘導体及び該誘導体を含有する抗精神病薬組成物 | |
| US6008216A (en) | Process for preparing 2-methyl-thieno-benzodiazepine | |
| US5229382A (en) | 2-methyl-thieno-benzodiazepine | |
| US6187788B1 (en) | Condensed-ring thiophene derivatives, their production and use | |
| US5605897A (en) | 2-methyl-thieno-benzodiazepine | |
| US6034078A (en) | Thienobenzodiazepine compounds | |
| JP2012502104A (ja) | 疾患の治療のためのヒスタミン受容体に対するアミノピリミジン阻害剤 | |
| CZ290464B6 (cs) | 3-Substituované 3,4-dihydrothieno[2,3-d]pyrimidinové deriváty, jejich příprava a pouľití | |
| EP0655451B1 (en) | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | |
| JPH02202887A (ja) | ４，４ａ，５，６，７，８，８ａ，９―オクタヒドロ―１Ｈ―ピラゾロ〔３，４―ｇ〕イソキノリン誘導体 | |
| EP1216250B1 (en) | Thienoisoxazolyl and thienylpyrrazolyl phenoxy substituted propyl derivatives useful as d4 antagonists | |
| US5817657A (en) | Psychoactive substance disorders | |
| WO1993013104A1 (en) | C.n.s. active tricyclic thienopyridine derivatives | |
| SK1052000A3 (en) | 3-substituted 3,4,5,7-tetrahydro-pyrrolo[3',4':4,5]thieno[2,3-d] pyrimidine derivatives, their preparation and use as 5ht antagonists | |
| EP0394471A1 (en) | Thienocycloheptapyridazine compounds and medicinal uses thereof | |
| DK162050B (da) | Pyrazolderivater med ergolinskelet eller salte deraf, deres fremstilling, farmaceutiske praeparater indeholdende disse og fremgangsmaade til fremstilling af de farmaceutiske praeparater | |
| KR100273622B1 (ko) | 티에노벤조디아제핀 유도체, 이의 제조방법 및 이를 포함하는 약제학적 제형 | |
| US6593324B2 (en) | Dervatives of quinoline as alpha-2 antagonists | |
| CN101228131A (zh) | 新的杂环亚基乙酰胺衍生物 | |
| US5028602A (en) | Pharmaceutical compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20020528 |